ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

MOLECULAR AND CELLULAR NEUROSCIENCE, published by Academic Press Inc Elsevier Science, is a pivotal journal dedicated to the expansive fields of Cellular and Molecular Neuroscience, providing a platform for the dissemination of innovative research and theoretical advancements since its establishment in 1990. With an ISSN of 1044-7431 and a commitment to high scholarly standards, this journal holds a notable Q2 ranking in key categories such as Cell Biology and Molecular Biology, highlighting its significant impact within the academic community. Although currently not an Open Access journal, it offers a wealth of insightful contributions aimed at fostering understanding and collaboration among researchers, professionals, and students. The journal's ongoing publication trajectory through to 2024 guarantees a continuous flow of cutting-edge research that is critical for addressing complex questions in neuroscience. As it plays a crucial role in advancing our understanding of molecular mechanisms underpinning neural function and pathology, MOLECULAR AND CELLULAR NEUROSCIENCE remains an essential reference for anyone invested in these dynamic fields.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Neural Regeneration Research is a premier Open Access journal, published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of Developmental Neuroscience. Since its inception, the journal has established itself as a valuable resource for researchers, professionals, and students alike, providing a comprehensive platform for disseminating the latest findings and methodologies in neural regeneration. With an impressive Scopus Ranks placement of #3 out of 49 in its category and a Q2 Quartile ranking, the journal boasts a significant impact within the academic community, reflecting its high quality and relevance. Since adopting an Open Access model in 2011, it has expanded access to critical research in neural regeneration, fostering collaboration and innovation among scholars globally. Covering various aspects of neuroscience, its converged years from 2006 to 2025 highlight the journal's commitment to ongoing discourse and discovery. Situated in China, the journal not only promotes local insights but also connects the global research community to pressing topics in neuroscience, making it an essential read for anyone involved in this dynamic field.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.